146 related articles for article (PubMed ID: 3497883)
1. In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells.
Brunda MJ; Bellantoni D; Sulich V
Int J Cancer; 1987 Sep; 40(3):365-71. PubMed ID: 3497883
[TBL] [Abstract][Full Text] [Related]
2. Interaction of recombinant interferons with recombinant interleukin-2: differential effects on natural killer cell activity and interleukin-2-activated killer cells.
Brunda MJ; Tarnowski D; Davatelis V
Int J Cancer; 1986 May; 37(5):787-93. PubMed ID: 2422129
[TBL] [Abstract][Full Text] [Related]
3. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
4. Antitumor and antimetastatic activity of interleukin 12 against murine tumors.
Brunda MJ; Luistro L; Warrier RR; Wright RB; Hubbard BR; Murphy M; Wolf SF; Gately MK
J Exp Med; 1993 Oct; 178(4):1223-30. PubMed ID: 8104230
[TBL] [Abstract][Full Text] [Related]
5. In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors.
Iigo M; Sakurai M; Tamura T; Saijo N; Hoshi A
Cancer Res; 1988 Jan; 48(2):260-4. PubMed ID: 2446744
[TBL] [Abstract][Full Text] [Related]
6. Analysis of metastatic spread and growth of tumor cells in mice with depressed natural killer activity by anti-asialo GM1 antibody or anticancer agents.
Saijo N; Ozaki A; Beppu Y; Takahashi K; Fujita J; Sasaki Y; Nomori H; Kimata M; Shimizu E; Hoshi A
J Cancer Res Clin Oncol; 1984; 107(3):157-63. PubMed ID: 6736102
[TBL] [Abstract][Full Text] [Related]
7. Effects of interleukin-2 and interferon-alpha A/D treatment on lymphocytes from tumour-bearing mice.
Ligo M; Nakajima Y; Nishikata K; Hoshi A
Br J Cancer; 1989 Jun; 59(6):883-8. PubMed ID: 2786729
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of experimentally-induced murine metastases by recombinant alpha interferon: correlation between the modulatory effect of interferon treatment on natural killer cell activity and inhibition of metastases.
Brunda MJ; Rosenbaum D; Stern L
Int J Cancer; 1984 Sep; 34(3):421-6. PubMed ID: 6480158
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2.
Hinuma S; Naruo K; Shiho O; Tsukamoto K
Immunology; 1986 Oct; 59(2):251-9. PubMed ID: 3490435
[TBL] [Abstract][Full Text] [Related]
10. Changes in lymphocyte subsets following multiple administration of recombinant interleukin-2 plus recombinant interferon-beta or -gamma in tumor-bearing mice.
Iigo M; Nishikata K; Nakajima Y; Moriyama M
Jpn J Cancer Res; 1989 Jun; 80(6):554-61. PubMed ID: 2527216
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-18 in combination with IL-2 enhances natural killer cell activity without inducing large amounts of IFN-gamma in vivo.
Arai N; Akamatsu S; Arai S; Toshimori Y; Hanaya T; Tanimoto T; Ikeda M; Tomura M; Fujiwara H; Kurimoto M
J Interferon Cytokine Res; 2000 Feb; 20(2):217-24. PubMed ID: 10714558
[TBL] [Abstract][Full Text] [Related]
12. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
13. Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2.
Hornung RL; Back TC; Zaharko DS; Urba WJ; Longo DL; Wiltrout RH
J Immunol; 1988 Nov; 141(10):3671-9. PubMed ID: 2460546
[TBL] [Abstract][Full Text] [Related]
14. [Immunotherapy of malignant lymphoma with interleukin-2 and sizofiran--a basic study on EL-4 lymphoma-transplanted mice].
Hashimoto J
Nihon Jibiinkoka Gakkai Kaiho; 1994 Jul; 97(7):1235-49. PubMed ID: 8064508
[TBL] [Abstract][Full Text] [Related]
15. Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice.
McIntosh JK; Mulé JJ; Krosnick JA; Rosenberg SA
Cancer Res; 1989 Mar; 49(6):1408-14. PubMed ID: 2784349
[TBL] [Abstract][Full Text] [Related]
16. Generation of mouse natural killer (NK) cell activity: effect of interleukin-2 (IL-2) and interferon (IFN) on the in vivo development of natural killer cells from bone marrow (BM) progenitor cells.
Riccardi C; Giampietri A; Migliorati G; Cannarile L; D'Adamio L; Herberman RB
Int J Cancer; 1986 Oct; 38(4):553-62. PubMed ID: 2944847
[TBL] [Abstract][Full Text] [Related]
17. Combined effects of intraperitoneal administration of recombinant interleukin-2 and streptococcal preparation OK-432 in murine tumors.
Fujioka T; Ishikura K; Tanji S; Okamoto T; Koike H; Aoki H; Ohhori T; Kubo T
Int J Immunopharmacol; 1990; 12(4):419-26. PubMed ID: 2391188
[TBL] [Abstract][Full Text] [Related]
18. In vivo effects of recombinant human interleukin 2 on antitumor and antiviral natural immunity in induced or natural murine immunodeficiency states.
Butler LD; Browne CP; Layman NK; Riedl P; Tang J; Marder P; DeLong D; Manetta J; Bobbitt L; Strnad J
Cancer Res; 1988 Nov; 48(21):6081-9. PubMed ID: 3048654
[TBL] [Abstract][Full Text] [Related]
19. Recombinant interleukin-2 inhibits growth of human tumor xenografts in congenitally athymic mice.
Bubeník J; Kieler J; Tromholt V; Indrová M; Lotzová E
Immunol Lett; 1987 Apr; 14(4):325-30. PubMed ID: 3495490
[TBL] [Abstract][Full Text] [Related]
20. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]